+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Peptichemio in pretreated patients with ovarian cancer

Cancer Treatment Reports 69(1): 17-20

Peptichemio in pretreated patients with ovarian cancer

From January 1978 to October 1982, 47 patients with histological diagnosis of epithelial cancer of the ovary received peptichemio (PTC) at a dose of 70 mg/m2 (maximum, 120 mg total) every 15 days. Forty-two patients are now evaluable: 27 with stage III and 15 with stage IV disease. All patients but four with stage IV disease had been pretreated and had received at least one drug combination (median, three drugs per patient, including alkylating agents). Before the administration of PTC, the tumor extension in the abdomen was carefully assessed in all patients: ten patients had residual tumor less than 2 cm in diameter, while 32 patients had tumor greater than 2 cm in diameter. Objective responses were obtained in ten patients (23.8%): six complete remissions and one partial remission were observed in stage III patients and one complete remission and two partial remissions were observed in stage IV patients. Of the ten responding patients, eight had tumors less than 2 cm in diameter before receiving PTC. The median duration of response was 16 months. The most frequent side effects were myelosuppression and phlebosclerosis. Bone marrow depression was a common finding after the third course in heavily pretreated patients. Accordingly, in these patients a schedule interval of 3 weeks should be more appropriate. Since most of the responders were in the "small tumor" category, PTC appears to be an active drug in patients with ovarian cancer having small tumors (less than 2 cm). On the other hand, the response rate in a nonselected population of patients remains to be clearly defined with further studies.

Accession: 006079561

PMID: 3155650

Related references

Paccagnella, A.; Salvagno, L.; Chiarion-Sileni, V.; Bolzonella, S.;, P.; Frizzarin, M.; Pappagallo, G.L.; Fosser, V.P.; Fornasiero, A.; Segati, R., 1986: Peptichemio in pretreated patients with plasmacell neoplasms. Twenty-one patients with alkylator-resistant plasmacell neoplasms were treated with Peptichemio (PTC) at a dose of 40 mg/m2 for 3 days every 3 weeks or, in the case of persistent leukopenia and/or thrombocytopenia, at the single dose of 70 mg/m2 e...

Klaassen, U.; Wilke, H.; Strumberg, D.; Eberhardt, W.; Korn, M.; Seeber, S., 1995: Phase I study with weekly paclitaxel infusion in heavily pretreated advanced breast cancer and ovarian cancer patients. Onkologie 18(SUPPL 2): 100

Guastalla, J.P.; Martin, C.; Tigaud, D.; Dramais, D.; Levy, E.; Leduc, B.; Vincent, P.; Paraiso, D.I.; Pujade Lauraine, E., 1999: Epirubicin + paclitaxel in pretreated advanced ovarian cancer patients. European Journal of Cancer 35(SUPPL 4): S243, Sept

Garaventa, A.; D.B.rnardi, B.; Cordero D.M.ntezemolo, L.; Pastore, G.; D.L.urentis, C.; Nardi, E.; Casale, F.; Mancini, A.; Loiacono, G., 1989: High dose peptichemio in pretreated neuroblastoma. The aim of this study was to evaluate the antitumor effect and toxicity of a single course of Peptichemio at high dose (450 mg/sq m) given to children with neuroblastoma resistant to first line treatment or at relapse. A total of 28 children were...

Bodnar, L.; Wcislo, G.; Nasilowska, A.; Szarlej-Wcislo, K.; Gasowska-Bodnar, A.; Smoter, M.; Szczylik, C., 2008: Salvage therapy with topotecan in heavily pretreated ovarian cancer patients. We showed feasibility and efficacy of topotecan in third or a higher line of chemotherapy in heavily pretreated ovarian cancer (HPOC) patients. Between January 2004 and June 2007, 25 cases of HPOC were treated with topotecan as 30-min infusion at...

Bilgin, T.; Ozalp, S.; Yalçin, O.T.; Zorlu, G.; Vardar, M.A.; Ozerkan, K., 2003: Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients. Single agent gemcitabine was used in recurrent epithelial ovarian cancer patients after standard treatment with debulking surgery and platin-paclitaxel based chemotherapy. Response rates and toxicity results were evaluated retrospectively. Gemcita...

Zelenka, P.; Kier, P.; Ruckser, R.; Habertheuer, K.H.; Sebesta, C.; Selleny, S.; Hinterberger, W., 1995: Taxol in heavily pretreated patients with advanced breast and ovarian cancer. Onkologie 18(SUPPL 2): 100

Calcagno, M.; Bellati, F.; Palaia, I.; Plotti, F.; Basile, S.; Pastore, M.; Sansone, M.; Arrivi, C.; Angioli, R.; Panici, P.Benedetti., 2009: Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients. To evaluate the clinical benefit of a 3-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients scheduled for palliative treatment. Eligibility criteria were 2 or more prior chemotherapy regimens, Eastern Cooperative Oncolog...

Chura, J.C.; Van Iseghem, K.; Downs, L.S.; Carson, L.F.; Judson, P.L., 2007: Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Objective. To investigate the efficacy and safety of bevacizumab in heavily pretreated patients with recurrent ovarian cancer.Methods. Patients with recurrent ovarian cancer were treated with intravenous bevacizumab 10 mg/kg every other week plus...

Wcislo, G.B.; Bodnar, L.; Nasilowska, A.; Szarlej-Wcislo, K.; Szczylik, C., 2016: Topotecan therapy as salvage in heavily pretreated ovarian cancer patients (hpocp). NlmCategory="UNASSIGNED">15057 Background: Topotecan is utilized as to a second-line chemotherapy agent in ovarian cancer. The third or more line of chemotherapy is possibly to use against ovarian cancer which is chemosensitive even w...